The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer.
about
Candida pseudorugosa sp. nov., a novel yeast species from sputum.Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: an analysis of microbiological data.Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria.Effect of antifungal therapy timing on mortality in cancer patients with candidemiaEvaluation of the antifungal activity of olive leaf aqueous extracts against Candida albicans PTCC-5027.Risk factors for fluconazole-resistant Candida glabrata bloodstream infectionsUPC2A is required for high-level azole antifungal resistance in Candida glabrata.Candidaemia and cancer: patients are not all the same.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisGlycosylation status of the C. albicans cell wall affects the efficiency of neutrophil phagocytosis and killing but not cytokine signaling.Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasisSyk signaling in dendritic cells orchestrates innate resistance to systemic fungal infection.Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsInvasive aspergillosis in patients with hematologic malignancies.Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaGenome-wide replication landscape of Candida glabrata.Active surveillance for candidemia, AustraliaInvasive fungal infections in acute leukemia.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.Pediatric Risk Factors for Candidemia Secondary to Candida glabrata and Candida krusei Species.Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.Blood stream infections by Candida glabrata and Candida krusei: a single-center experienceIncidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.A scoring model of factors associated with Candida glabrata candidemia among critically ill patients.Invasive fungal infections in newborns and current management strategies.Epidemiology and risk factors for nosocomial Non-Candida albicans candidemia in adult patients at a tertiary care hospital in North China.Azole Resistance in Candida glabrata.In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.Relationships between respiration and susceptibility to azole antifungals in Candida glabrata.Protective role of naturally occurring interleukin-17A-producing γδ T cells in the lung at the early stage of systemic candidiasis in mice.Comparison of Mycosis IC/F and plus Aerobic/F media for diagnosis of fungemia by the bactec 9240 system.Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010.β-Aescin at subinhibitory concentration (sub-MIC) enhances susceptibility of Candida glabrata clinical isolates to nystatin.Invasive fungal infections in pediatric hematopoietic stem cell transplant patients.Synthesis and Biological Evaluation of Novel Alkyl-Imidazolyl Carbinols and their Esters: Potent Antimycotics.Invasive Candida infections in patients with haematological malignancies and hematopoietic stem cell transplant recipients: current epidemiology and therapeutic options.Candidaemia in patients with haematological disorders and stem cell transplant.In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.
P2860
Q31064491-C7911288-D11D-4125-B2D3-F8C24625A087Q31152900-9B3C2097-DE83-43FC-82C5-FDD5F9B94677Q33202199-31FB2CC4-BFA2-461A-80AB-FD2F74F39531Q33559164-D4E01876-3B85-4382-8495-A00E7B386DE7Q33851278-71CDC3FB-20D7-422D-BF32-CC545D946F23Q33932340-BD176E60-E0CF-4917-9BBA-2C046DAFCD50Q34058180-26F5CA22-C733-42E4-9BF0-3FE549E3EEC6Q34521837-EB8C4893-CE19-4C05-B0F4-E4A5F4060DDBQ35026516-D533F0B7-75EF-4C4F-B6DD-9DB625E27665Q35059329-077CE5FC-65CE-41A0-97EE-44FE4EFAF620Q35127833-14075C38-E043-4E7D-99F5-153EF17DBC13Q35208352-9A1B00DF-7E3E-4D0F-9494-838DC017F9D7Q35270758-99BCC2F9-542F-45D1-BBE3-6EE5345BF692Q35616161-3CE5C245-11BE-438C-99B1-73377C7B02E0Q35647785-65BB7246-2999-4897-A155-C0C2BFBA3747Q35761459-72965124-26C3-431D-B543-FB8EA50BEF2BQ35792197-EA72BE23-49BB-43DB-8082-799278177640Q36612597-C1A8010F-465C-41CD-98E8-F51EE3453C26Q36828156-F8774A11-1BFB-4A9A-83E8-5C4E38523BA8Q37142716-08B84FE3-D0E5-4123-8A52-CCC3DDCBAE21Q37291442-FB0BE93D-4FD3-49E2-B30C-B558FA3015B5Q37320979-E5363206-F3B8-4683-AC7D-B2BA7ECABAD8Q37420953-79026F6D-2C35-470F-BF35-5398EC71499AQ37816399-E4E05848-EC95-4181-996E-9E89B6C5D989Q37900678-AA3CD384-D0E0-4E8F-9F09-C6ACD2D098E6Q37903392-1C884D75-F32A-465A-85AD-B38C318738CBQ38119554-02D7A11F-559A-41CE-BC17-96ED977B08D1Q38558193-492EB71B-7EC7-48FA-9227-04F773962FFCQ38985818-EAFE9D28-EE29-477B-B2B8-DC32340B8358Q39077602-D9C9E5DB-7198-4921-B8C4-D59FB4DA0BFFQ39731901-E54360F7-E3D2-43CA-BD19-946AD58D84D1Q40387405-B1CE5BE3-D4DF-4E61-849A-C66311C31D1EQ40585382-626E74DB-71E9-4A6E-A5E3-108017648067Q40757551-3043439C-EF74-420A-AB42-0FEFFD31CE08Q40819010-10CE60E1-943F-4CF3-B2E6-846EBB174D8AQ41480974-6B28EEC3-0220-447B-A410-920B9FFDAABEQ42042096-6D40BF2A-6DBA-490B-BB74-9CA69941D906Q42119440-F9DEBD89-C4B2-4A32-AF1C-B11DBF643343Q42200421-4E62FD14-599D-47F8-9759-278988BE763DQ42845954-147107CF-ABBB-4E8C-92C7-F315AB15E570
P2860
The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The epidemiology of Candida gl ...... promised patients with cancer.
@en
The epidemiology of Candida gl ...... promised patients with cancer.
@nl
type
label
The epidemiology of Candida gl ...... promised patients with cancer.
@en
The epidemiology of Candida gl ...... promised patients with cancer.
@nl
prefLabel
The epidemiology of Candida gl ...... promised patients with cancer.
@en
The epidemiology of Candida gl ...... promised patients with cancer.
@nl
P2093
P1476
The epidemiology of Candida gl ...... promised patients with cancer.
@en
P2093
Dimitrios P Kontoyiannis
Essam Girgawy
Gerald P Bodey
Hend A Hanna
Issam I Raad
Jalal Abbas
Maha Boktour
Masoud Mardani
Ray Y Hachem
P304
P356
10.1016/S0002-9343(01)01130-5
P407
P577
2002-04-01T00:00:00Z